Mural Oncology plc

Historical 13F Holders

Symbol
MURA
CUSIP
G63365103
All holders as of
Q3 2025
Type
Equity
Class
ORD SHS
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for G63365103 since 12/18/2024, newest first.

Filer % of Class Filed
Trium Capital LLP 13G/A Amendment 1 0% 12/16/2025
Event 12/11/2025
Prosight Management, LP 13G/A Amendment 1
0% 11/13/2025
Event 9/30/2025
Soleus Capital Master Fund, L.P. 13G/A Amendment 2
0% 11/7/2025
Event 9/30/2025
Trium Capital LLP 13G 10.2% 9/2/2025
Event 8/22/2025
Solas Capital Management, LLC 13G/A Amendment 2
0% 8/14/2025
Event 6/30/2025
Armistice Capital, LLC 13G/A Amendment 4
0% 8/14/2025
Event 6/30/2025
Soleus Capital Master Fund, L.P. 13G/A Amendment 1
7.6% 8/5/2025
Event 6/30/2025
Prosight Management, LP 13G
5.2% 6/26/2025
Event 6/23/2025
Solas Capital Management, LLC 13G/A Amendment 1
5.2% 5/15/2025
Event 3/31/2025
Armistice Capital, LLC 13G/A Amendment 3
10.0% 5/15/2025
Event 3/31/2025
Stuart Feldman 13G
4.4% 5/14/2025
Event 4/16/2025
Soleus Capital Master Fund, L.P. 13G
6.3% 4/16/2025
Event 4/15/2025
Acorn Bioventures, L.P. 13G/A Amendment 2
7.6% 2/14/2025
Event 12/31/2024
Armistice Capital, LLC 13G/A Amendment 2
10.0% 2/14/2025
Event 12/31/2024
Acorn Bioventures, L.P. 13G/A Amendment 1
6.3% 11/14/2024
Event 8/9/2024
Solas Capital Management, LLC 13G
7.4% 11/14/2024
Event 9/30/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2025 Q3 67 5.49 M $11.4 M
2025 Q2 73 8.23 M $20.3 M
2025 Q1 73 8.40 M $10.6 M
2024 Q4 83 10.8 M $34.8 M
2024 Q3 77 9.52 M $29.8 M
2024 Q2 90 11.0 M $34.3 M
2024 Q1 105 12.5 M $61.3 M
2023 Q4 127 13.6 M $80.7 M